US 12,570,656 B2Granted

Purine compounds for treating disorders

AssigneeMarvel Biotechnology

InventorMark Williams

Life of this patent

Estimating the term…

Abstract

Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.

Claims11

Dependent claims

A compound of formula

or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 17/910,529Filed 9 Mar 2021 · us provisional application
Priority: 10 Mar 2020
Published: US 2023/0151011 A118 May 2023
Granted: 10 Mar 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

C07D 473/22
With oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6: one oxygen and one sulfur atom
A61K 31/522
Purines, e.g. adenine: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61P 25/00
Drugs for disorders of the nervous system
A61P 25/16
For treating abnormal movements, e.g. chorea, dyskinesia: anti-Parkinson drugs

Family

Application62/987,533Us provisional application · filed 10 Mar 2020
US 2023/0151011 A1Pre-grant publication · published 18 May 2023
US 12,570,656 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results